Key insights
- Compass Pathways stock experienced a significant decline, attributed to a broad market selloff impacting high-beta biotech names and a general risk-off sentiment. While the company has had positive developments, upcoming Phase 3 data for COMP006 presents a binary risk. The broader market's downturn, with major indices falling, exacerbates the pressure on pre-revenue biotechs. Despite positive analyst commentary comparing COMP360 to Johnson & Johnson's Spravato, the current market environment is a significant headwind.
Investing.com -- Shares of Compass Pathways fell 9.3% in afternoon trading to reach $11.83, retreating sharply from recent highs with no fresh company-specific catalyst to explain the move, as a broad market selloff swept through high-beta biotech names. The stock had been trading near its 52-week high of $14.76 after a powerful rally fueled by a series of positive corporate developments over the past several weeks.
Adding to the cautious tone today, investors may be trimming exposure ahead of the upcoming COMP006 Phase 3 26-week Part B durability data, expected in early Q3 2026 — a binary event that carries meaningful risk in either direction. The broader U.S. equity market is offering no support, with the S&P 500 declining 2.2%, the Dow Jones off 1.0%, and the NASDAQ dropping 3.8%, creating a risk-off environment that disproportionately weighs on pre-revenue, high-beta biotechs like CMPS.
Further, Jefferies said COMP360 should exceed 2027 consensus estimates of $60 million, citing the $2 billion annual revenue generated by Johnson & Johnson’s Spravato, an intranasal esketamine treatment for the same indication. Spravato is administered at more than 7,500 sites, growing from approximately 4,000 in 2025, and has treated fewer than 100,000 U.S. patients in a total addressable market exceeding 4 million patients. The 26-week data from Study 006 will provide information on efficacy durability after two upfront doses. Phase III studies 006 and 005 already met their primary endpoint at Week 6, showing a -3.6 to -3.8 point difference versus placebo or 1mg COMP360 on the Montgomery-Åsberg Depression Rating Scale. COMP360’s label could allow for one to two initial doses and episodic retreatment of two to four additional doses per year, compared with up to 56 doses annually for Spravato. The treatment-resistant depression label should be broad, covering both monotherapy and adjunct therapy, and pricing will be competitive with Spravato’s $30,000 to $70,000 cost.
Taken together, the absence of fresh positive catalysts, the stock’s proximity to multi-year highs, looming binary clinical data risk, and a deeply negative macro backdrop have combined to push CMPS sharply lower today — a pullback that, for now, reflects technical consolidation rather than any deterioration in the company’s underlying regulatory or clinical trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.